Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost

The VRC 307 and VRC 309 Study Teams

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008-2009 and 2009-2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime-boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA-IIV3) was compared to placebo (PBS)-IIV3 or IIV3-IIV3. Cumulatively, 111 adults were randomized to HA DNA-IIV3 (n = 66), PBS-IIV3 (n = 25) or IIV3-IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime-IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5. days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA-IIV3 regimen, but the 3-4. week prime-boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime-boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity.Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309.

Original languageEnglish (US)
Pages (from-to)112-118
Number of pages7
JournalContemporary Clinical Trials
Volume44
DOIs
StatePublished - Sep 1 2015
Externally publishedYes

Fingerprint

Inactivated Vaccines
DNA Vaccines
Influenza Vaccines
Hemagglutinins
Human Influenza
DNA
Vaccination
Safety
Appointments and Schedules
Placebos
Hemagglutination
Vaccines

Keywords

  • DNA vaccine
  • Immune response
  • Seasonal influenza

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)

Cite this

Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost. / The VRC 307 and VRC 309 Study Teams.

In: Contemporary Clinical Trials, Vol. 44, 01.09.2015, p. 112-118.

Research output: Contribution to journalArticle

@article{4d52d912c42b49e98a2d15da64125fee,
title = "Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost",
abstract = "Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008-2009 and 2009-2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime-boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA-IIV3) was compared to placebo (PBS)-IIV3 or IIV3-IIV3. Cumulatively, 111 adults were randomized to HA DNA-IIV3 (n = 66), PBS-IIV3 (n = 25) or IIV3-IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime-IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5. days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA-IIV3 regimen, but the 3-4. week prime-boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime-boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity.Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309.",
keywords = "DNA vaccine, Immune response, Seasonal influenza",
author = "{The VRC 307 and VRC 309 Study Teams} and Ledgerwood, {Julie E.} and Zonghui Hu and Pamela Costner and Galina Yamshchikov and Enama, {Mary E.} and Sarah Plummer and Hendel, {Cynthia S.} and Lasonji Holman and Brenda Larkin and Ingelise Gordon and Bailer, {Robert T.} and Poretz, {Donald M.} and Sarwar, {Uzma N.} and Alisha Kabadi and Richard Koup and Mascola, {John R.} and Graham, {Barney S.} and Laura Novik and Floreliz Mendoza and Jamie Saunders and Kathryn Zephir and Diane Johnson and Sandra Sitar and Olga Vasilenko and Joseph Casazza and Sheryl Young and Charla Andrews and Michelle Conan-Cibotti and Richard Jones and Hope Decederfelt and Judith Starling and Phyllis Renehan and Meghan Kunchai and Ly Diep and Barry Eagel",
year = "2015",
month = "9",
day = "1",
doi = "10.1016/j.cct.2015.08.006",
language = "English (US)",
volume = "44",
pages = "112--118",
journal = "Contemporary Clinical Trials",
issn = "1551-7144",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Phase I clinical evaluation of seasonal influenza hemagglutinin (HA) DNA vaccine prime followed by trivalent influenza inactivated vaccine (IIV3) boost

AU - The VRC 307 and VRC 309 Study Teams

AU - Ledgerwood, Julie E.

AU - Hu, Zonghui

AU - Costner, Pamela

AU - Yamshchikov, Galina

AU - Enama, Mary E.

AU - Plummer, Sarah

AU - Hendel, Cynthia S.

AU - Holman, Lasonji

AU - Larkin, Brenda

AU - Gordon, Ingelise

AU - Bailer, Robert T.

AU - Poretz, Donald M.

AU - Sarwar, Uzma N.

AU - Kabadi, Alisha

AU - Koup, Richard

AU - Mascola, John R.

AU - Graham, Barney S.

AU - Novik, Laura

AU - Mendoza, Floreliz

AU - Saunders, Jamie

AU - Zephir, Kathryn

AU - Johnson, Diane

AU - Sitar, Sandra

AU - Vasilenko, Olga

AU - Casazza, Joseph

AU - Young, Sheryl

AU - Andrews, Charla

AU - Conan-Cibotti, Michelle

AU - Jones, Richard

AU - Decederfelt, Hope

AU - Starling, Judith

AU - Renehan, Phyllis

AU - Kunchai, Meghan

AU - Diep, Ly

AU - Eagel, Barry

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008-2009 and 2009-2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime-boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA-IIV3) was compared to placebo (PBS)-IIV3 or IIV3-IIV3. Cumulatively, 111 adults were randomized to HA DNA-IIV3 (n = 66), PBS-IIV3 (n = 25) or IIV3-IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime-IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5. days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA-IIV3 regimen, but the 3-4. week prime-boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime-boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity.Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309.

AB - Annual influenza vaccination reduces the risks of influenza when the vaccines are well matched to circulating strains, but development of an approach that induces broader and more durable immune responses would be beneficial. We conducted two companion Phase 1 studies, VRC 307 and VRC 309, over sequential seasons (2008-2009 and 2009-2010) in which only the influenza B strain component of the vaccines differed. Objectives were safety and immunogenicity of prime-boost vaccination schedules. A schedule of DNA vaccine encoding for seasonal influenza hemagglutinins (HA) prime followed by seasonal trivalent influenza inactivated vaccine (IIV3) boost (HA DNA-IIV3) was compared to placebo (PBS)-IIV3 or IIV3-IIV3. Cumulatively, 111 adults were randomized to HA DNA-IIV3 (n = 66), PBS-IIV3 (n = 25) or IIV3-IIV3 (n = 20). Safety was assessed by clinical observations, laboratory parameters and 7-day solicited reactogenicity. The seasonal HA DNA prime-IIV3 boost regimen was evaluated as safe and well tolerated. There were no serious adverse events. The local and systemic reactogenicity for HA DNA, IIV and placebo were reported predominantly as none or mild within the first 5. days post-vaccination. There was no significant difference in immunogenicity detected between the treatment groups as evaluated by hemagglutination inhibition (HAI) assay. The studies demonstrated the safety and immunogenicity of seasonal HA DNA-IIV3 regimen, but the 3-4. week prime-boost interval was suboptimal for improving influenza-specific immune responses. This is consistent with observations in avian H5 DNA vaccine prime-boost studies in which a long interval, but not a short interval, was associated with improved immunogenicity.Trial Registration: NCT00858611 for VRC 307 and NCT00995982 for VRC 309.

KW - DNA vaccine

KW - Immune response

KW - Seasonal influenza

UR - http://www.scopus.com/inward/record.url?scp=84939611560&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939611560&partnerID=8YFLogxK

U2 - 10.1016/j.cct.2015.08.006

DO - 10.1016/j.cct.2015.08.006

M3 - Article

VL - 44

SP - 112

EP - 118

JO - Contemporary Clinical Trials

JF - Contemporary Clinical Trials

SN - 1551-7144

ER -